Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of aH5N1 Vaccine in Adults and Elderly
NCT02091908Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of MF59-eH5N1 in Influenza A H5N1 (H5N1), sponsored by CSL Seqirus. Started Apr 2014; status: completed.
02
Drugs
MF59-eH5N1
03
Conditions
Influenza A H5N1 (H5N1)
Beyond the preview
Go deeper on NCT02091908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091908.